Breast cancer imaging with radioiodinated oestradiol

Schober, Otmar; Scheidhauer, Klemens; Jackisch, Christian; Schicha, H.; Smolarz, Kamilla; Bolte, A.; Reiners, Christoph; Höffken, K.; Biersack, Hans‐Jürgen; Briele, B.; Moser, E.; Bräutigam, Peter

doi:10.1016/0140-6736(90)93056-u

Cited by 36 publications

(6 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…To date, no ER targeted radiopharmaceuticals are in routine clinical use. Two compounds that have shown considerable promise are the positron emission tomography (PET) agent 16α-[ 18 F]-fluoro-17β-estradiol (FES) (Figure B), for which clinical trials have been reported, and the single photon emission computed tomography (SPECT) tracer, cis -methoxy-[ 123 I]-iodovinylestradiol ( cis -MIVE) (Figure C), for which preclinical trials have been reported . FES uptake in primary tumors is directly related to the level of ER expression and FES-PET scanning has shown a positive correlation between the presence of ER positive tumors and responses to hormonal therapy.…”

Section: Introductionmentioning

confidence: 99%

Synthesis and Screening of Mono- and Di-Aryl Technetium and Rhenium Metallocarboranes. A New Class of Probes for the Estrogen Receptor

2008

View full text Add to dashboard Cite

A series of mono and diaryl rhenium(I)-carborane derivatives were prepared using microwave heating and screened for their affinity for two isoforms of the estrogen receptor (ER). The rhenacarborane derivative [(RR'C 2B9H9)Re(CO)3](-) (R = p-PhOH, R' = H), which was generated by taking advantage of a recently discovered cage isomerization process, and the neutral nitrosated analogue [(RR'C2B9H9)Re(CO)2(NO)] (R = p-PhOH, R' = H) showed the highest affinities of the compounds screened. As a result, the (99m)Tc analogue of one of the leads was produced in high yield (84%) and specific activity in a manner that is suitable for routine production in support of future preclinical and molecular imaging studies.

show abstract

Section: Introductionmentioning

confidence: 99%

Synthesis and Screening of Mono- and Di-Aryl Technetium and Rhenium Metallocarboranes. A New Class of Probes for the Estrogen Receptor

2008

View full text Add to dashboard Cite

show abstract

“…14.4 ]IES showed ER-mediated uptake in the rabbit reproductive system and in ER-positive tumors in breast cancer patients, but no specifi city or sensitivity data were reported (Kenady et al 1993 ;Pavlik et al 1990 ;Scheidhauer et al 1991 ;Schober et al 1990 (Bennink et al 2001(Bennink et al , 2004Rijks et al 1997a , b ). Although both […”

Section: Spectmentioning

confidence: 92%

PET and SPECT Imaging of Steroid Hormone Receptors

Khayum

Doorduin

Glaudemans

et al. 2014

PET and SPECT of Neurobiological Systems

View full text Add to dashboard Cite

show abstract

“…However, additional studies to determine the value of these tamoxifen-derived tracers are mandatory. [32]. Since [ 123 I]IES is rapidly cleared from blood via the liver, gallbladder and intestines, imaging of tumors in the abdomen is difficult.…”

Section: Estrogen Receptor Imagingmentioning

confidence: 99%

Nuclear Imaging of Hormonal Receptor Status in Breast Cancer: A Tool for Guiding Endocrine Treatment and Drug Development

Vries¹,

Rots²,

Hospers³

2007

CCDT

View full text Add to dashboard Cite

Breast cancer is a commonly occurring disease in women and a major cause of morbidity and mortality. In the past decades, the development of medical endocrine therapies has led to a significant improvement in treatment outcome for this type of cancer. This therapy is targeting specific hormone receptors that are overexpressed by the tumor cells. In breast cancer, estrogen and progesterone receptors are important targets and therefore the receptor status of the tumor strongly determines treatment outcome. However, the receptor status can change during the course of the disease and consequently therapy resistance can occur. Therefore, insight in the current receptor status of the tumor is essential for optimal treatment. Nuclear imaging techniques like positron emission tomography (PET) and single photon emission computed tomography (SPECT), could provide the means to monitor the receptor status of tumors and the receptor occupancy by medical endocrine drugs in a non-invasive manner. Thus, these imaging techniques could offer a tool to guide therapy management in the individual patient. Nuclear imaging techniques for some of the relevant receptors for treatment of breast cancer are currently available. These imaging techniques could also aid the development of novel treatment strategies like modulation of hormone receptor expression. This review will address the role of hormone receptors in breast cancer treatment, the available nuclear imaging methods for monitoring the receptor status, the potential role of nuclear imaging in therapy management and drug development.

show abstract

Breast cancer imaging with radioiodinated oestradiol

Cited by 36 publications

References 1 publication

Synthesis and Screening of Mono- and Di-Aryl Technetium and Rhenium Metallocarboranes. A New Class of Probes for the Estrogen Receptor

Synthesis and Screening of Mono- and Di-Aryl Technetium and Rhenium Metallocarboranes. A New Class of Probes for the Estrogen Receptor

PET and SPECT Imaging of Steroid Hormone Receptors

Nuclear Imaging of Hormonal Receptor Status in Breast Cancer: A Tool for Guiding Endocrine Treatment and Drug Development

Contact Info

Product

Resources

About